phosphonoacetic acid and Adenocarcinoma, Basal Cell
phosphonoacetic acid has been researched along with Adenocarcinoma, Basal Cell in 26 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 9.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas." | 5.07 | A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992) |
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
" The extent of control of the EMT-6 mammary adenocarcinoma was determined using fractionated radiation (12 irradiations) over a 3-week period using the radiosensitizer 5-chloro-2'-deoxycytidine (CldC) and biomodulators of its metabolism: N-(Phosphonacetyl)-L-aspartate (PALA), tetrahydrouridine and 5-fluoro-2'-deoxycytidine (FdC)." | 3.69 | Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. ( Greer, S; Marion, HS; Schwade, J, 1995) |
"To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma." | 3.69 | Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997) |
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
"Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
"Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
"Both normal and colonic cancer cells, when cultured in the presence of these agents, cease to increase their cell numbers." | 1.26 | Antiproliferative agents and differential survival between normal and cancer cells. ( Kwong, LK; Tsuboi, KK, 1978) |
Research
Studies (26)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (26.92) | 18.7374 |
1990's | 16 (61.54) | 18.2507 |
2000's | 3 (11.54) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Johnston, PG | 1 |
Benson, AB | 1 |
Catalano, P | 1 |
Rao, MS | 1 |
O'Dwyer, PJ | 5 |
Allegra, CJ | 2 |
Whitehead, RP | 1 |
Benedetti, JK | 1 |
Abbruzzese, JL | 1 |
Ardalan, B | 3 |
Goodwin, JW | 1 |
Balcerzak, SP | 1 |
Samlowski, WE | 1 |
Lenz, HJ | 1 |
Macdonald, JS | 3 |
Rubin, J | 1 |
Schutt, AJ | 1 |
O'Connell, MJ | 1 |
Gertz, MA | 1 |
Moertel, CG | 1 |
Earhart, RH | 1 |
Elson, PJ | 1 |
Rosenthal, SN | 1 |
Hahn, RG | 1 |
Slayton, RE | 1 |
Natale, RB | 1 |
Yagoda, A | 1 |
Kelsen, DP | 1 |
Gralla, RJ | 1 |
Watson, RC | 1 |
Greer, S | 1 |
Schwade, J | 2 |
Marion, HS | 1 |
Redei, I | 1 |
Green, F | 1 |
Hoffman, JP | 1 |
Weiner, LM | 3 |
Scher, R | 1 |
Ucar, A | 1 |
Reddy, R | 1 |
Livingstone, AS | 1 |
Markoe, A | 1 |
Richman, SP | 3 |
Donofrio, K | 1 |
Grem, JL | 2 |
McAtee, N | 1 |
Steinberg, SM | 1 |
Hamilton, JM | 2 |
Murphy, RF | 1 |
Drake, J | 1 |
Chisena, T | 1 |
Balis, F | 1 |
Cysyk, R | 1 |
Arbuck, SG | 1 |
Hudes, GR | 1 |
Kitson, J | 1 |
Walczak, J | 3 |
Watts, P | 1 |
Litwin, S | 2 |
Yang, JL | 1 |
Fernandes, DJ | 1 |
Wheeler, KT | 1 |
Capizzi, RL | 1 |
Wadler, S | 1 |
Gleissner, B | 1 |
Hilgenfeld, RU | 1 |
Thiel, E | 1 |
Haynes, H | 1 |
Kaleya, R | 1 |
Rozenblit, A | 1 |
Kreuser, ED | 1 |
Ragnhammar, P | 1 |
Blomgren, H | 1 |
Martino, RL | 1 |
Fleming, TR | 2 |
Morrell, LM | 2 |
Köhne, CH | 2 |
Wilke, H | 2 |
Schöffski, P | 1 |
Schmoll, HJ | 2 |
Harstrick, A | 1 |
Hiddemann, W | 1 |
Preusser, P | 1 |
Strumberg, D | 1 |
Berns, T | 1 |
Seeber, S | 1 |
Yee, LK | 1 |
Schuler, B | 1 |
Chen, AP | 1 |
Chabuk, C | 1 |
Grollman, F | 1 |
Grabenc, M | 1 |
Takimoto, CH | 1 |
Tsuboi, KK | 1 |
Kwong, LK | 1 |
Kelsen, D | 1 |
Martin, DS | 2 |
Colofiore, J | 2 |
Sawyer, R | 1 |
Coit, D | 1 |
Rosvold, E | 1 |
Schilder, R | 1 |
DiFino, SM | 1 |
Flynn, PJ | 1 |
Banerjee, TK | 1 |
Heim, WJ | 1 |
Engstrom, PF | 1 |
Ozols, RF | 1 |
Kemeny, N | 2 |
Conti, JA | 1 |
Seiter, K | 1 |
Niedzwiecki, D | 1 |
Botet, J | 1 |
Martin, D | 1 |
Costa, P | 1 |
Wiseberg, J | 1 |
McCulloch, W | 1 |
Bach, A | 1 |
Goodman, P | 1 |
Paul, AR | 1 |
Comis, RL | 1 |
Schneider, A | 1 |
Sawyer, RC | 1 |
Derby, S | 1 |
Salvia, B | 1 |
Chiuten, DF | 2 |
Valdivieso, M | 2 |
Bedikian, A | 2 |
Bodey, GP | 2 |
Freireich, EJ | 2 |
Miller, A | 1 |
Loo, TL | 1 |
Benvenuto, JA | 1 |
Reviews
2 reviews available for phosphonoacetic acid and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
Trials
9 trials available for phosphonoacetic acid and Adenocarcinoma, Basal Cell
Other Studies
15 other studies available for phosphonoacetic acid and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
A phase II study of the combination, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and N-(phosphonacetyl)-L-aspartate (PALA), in patients with advanced large bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carmusti | 1984 |
Phase II study of PALA and AMSA in advanced renal cell carcinoma.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; A | 1983 |
Phase II trial of PALA in hypernephroma and urinary bladder cancer.
Topics: Adenocarcinoma; Aspartic Acid; Drug Evaluation; Humans; Kidney Neoplasms; Neoplasm Metastasis; Organ | 1982 |
Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
Topics: Adenocarcinoma; Animals; Aspartic Acid; Body Weight; Deoxycytidine; Idoxuridine; Mammary Neoplasms, | 1995 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartic Acid; Bromodeoxyuridine; Cell Division; DN | 1996 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac | 1997 |
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran | 2001 |
Antiproliferative agents and differential survival between normal and cancer cells.
Topics: Adenocarcinoma; Aspartic Acid; Cell Cycle; Cell Division; Cell Line; Cell Survival; Colonic Neoplasm | 1978 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |